Cai Jing Wang·2026-02-05 08:27Group 1 - The company plans to transfer 30% equity stake in its subsidiary, China-America Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd., through public listing at a minimum price of 1.023 billion yuan [1] - The purpose of the transaction is to optimize the investment structure and maximize asset value, with the final price determined by the public listing results [1][2] - The current ownership structure of China-America Bristol-Myers Squibb includes 60% held by Bristol-Myers Squibb (China) Investment Co., Ltd., 30% by the company, and 10% by China National Pharmaceutical Group Asset Management Co., Ltd. [1] Group 2 - Bristol-Myers Squibb (China) Investment Co., Ltd. intends to sell its 60% stake in China-America Bristol-Myers Squibb, with a potential buyer expected to submit a confirmation bid by June 2025 for a total acquisition price of 480 million USD, equivalent to 1.44 billion yuan for the company's 30% stake [1] - The company believes that achieving an exit through market-based pricing will better maximize asset value and protect the interests of all shareholders, especially minority shareholders [2]